Long Noncoding RNA NORAD, a Novel Competing Endogenous RNA, Enhances the Hypoxia-induced Epithelial-mesenchymal Transition to Promote Metastasis in Pancreatic Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2017 Nov 11

PMID 29121972

Citations 127

Authors

Hongzhe Li

Xinjing Wang

Chenlei Wen

Zhen Huo

Weishen Wang

Qian Zhan

Dongfeng Cheng

Hao Chen

Xiaxing Deng

Chenghong Peng

Baiyong Shen

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer, one of the top two most fatal cancers, is characterized by a desmoplastic reaction that creates a dense microenvironment, promoting hypoxia and inducing the epithelial-to-mesenchymal transition (EMT) to facilitate invasion and metastasis. Recent evidence indicates that the long noncoding RNA NORAD may be a potential oncogenic gene and that this lncRNA is significantly upregulated during hypoxia. However, the overall biological role and clinical significance of NORAD remains largely unknown.

Methods: NORAD expression was measured in 33 paired cancerous and noncancerous tissue samples by real-time PCR. The effects of NORAD on pancreatic cancer cells were studied by overexpression and knockdown in vitro. Insights into the mechanism of competitive endogenous RNAs (ceRNAs) were gained from bioinformatics analyses and luciferase assays. In vivo, metastatic potential was identified using an orthotopic model of PDAC and quantified using bioluminescent signals. Alterations in RhoA expression and EMT levels were identified and verified by immunohistochemistry and Western blotting.

Results: NORAD is highly expressed in pancreatic cancer tissues and upregulated in hypoxic conditions. NORAD upregulation is correlated with shorter overall survival in pancreatic cancer patients. Furthermore, NORAD overexpression promoted the migration and invasion of pancreatic carcinoma cells, while NORAD depletion inhibited EMT and metastasis in vitro and in vivo. In particular, NORAD may function as a ceRNA to regulate the expression of the small GTP binding protein RhoA through competition for hsa-miR-125a-3p, thereby promoting EMT.

Conclusions: Elevated expression of NORAD in pancreatic cancer tissues is linked to poor prognosis and may confer a malignant phenotype upon tumor cells. NORAD may function as a ceRNA to regulate the expression of the small GTP binding protein RhoA through competition for hsa-miR-125a-3p. This finding may contribute to a better understanding of the role played by lncRNAs in hypoxia-induced EMT and provide a potential novel diagnostic and therapeutic target for pancreatic cancer.

Citing Articles

The crosstalk between non-coding RNAs and oxidative stress in cancer progression.

Sun Q, Lei X, Yang X Genes Dis. 2025; 12(3):101286.

PMID: 40028033 PMC: 11870203. DOI: 10.1016/j.gendis.2024.101286.

Landscape of Noncoding RNA in the Hypoxic Tumor Microenvironment.

Gong L, Zou C, Zhang H, Yang F, Qi G, Ma Z Genes (Basel). 2025; 16(2).

PMID: 40004471 PMC: 11855738. DOI: 10.3390/genes16020140.

Decellularized tissue matrices hydrogels functionalized with extracellular vesicles promote macrophage reprogramming and neural stem cell differentiation for spinal cord injury repair.

Deng M, Xie P, Xue H, Chen Q, Zhou Y, Ming J J Nanobiotechnology. 2025; 23(1):139.

PMID: 40001048 PMC: 11853540. DOI: 10.1186/s12951-025-03152-0.

Long Non-Coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness.

Yuan Y, Tang Y, Fang Z, Wen J, Wicha M, Luo M Cells. 2025; 14(3).

PMID: 39937018 PMC: 11817775. DOI: 10.3390/cells14030227.

Competing endogenous RNAs network dysregulation in oral cancer: a multifaceted perspective on crosstalk and competition.

Wu J, Zhang C, Li H, Zhang S, Chen J, Qin L Cancer Cell Int. 2024; 24(1):431.

PMID: 39725978 PMC: 11673722. DOI: 10.1186/s12935-024-03580-2.

References

Pei H, Li L, Fridley B, Jenkins G, Kalari K, Lingle W . FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009; 16(3):259-66. PMC: 2755578. DOI: 10.1016/j.ccr.2009.07.016. View

Yang J, Li J, Shao P, Zhou H, Chen Y, Qu L . starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2010; 39(Database issue):D202-9. PMC: 3013664. DOI: 10.1093/nar/gkq1056. View

Li J, Liu S, Zhou H, Qu L, Yang J . starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013; 42(Database issue):D92-7. PMC: 3964941. DOI: 10.1093/nar/gkt1248. View

Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N . MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience. 2015; 1(4):250-261. PMC: 4278297. DOI: 10.18632/oncoscience.30. View

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

Lv J, Fan H, Zhao X, Lv P, Fan J, Zhang Y . Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells. Cancer Lett. 2016; 382(2):166-175. DOI: 10.1016/j.canlet.2016.08.029. View

Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X . miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. Acta Biochim Biophys Sin (Shanghai). 2015; 47(7):496-503. DOI: 10.1093/abbs/gmv039. View

Evelyn C, Wade S, Wang Q, Wu M, Iniguez-Lluhi J, Merajver S . CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007; 6(8):2249-60. DOI: 10.1158/1535-7163.MCT-06-0782. View

Lu M, Tang B, Zeng S, Hu C, Xie R, Wu Y . Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. Oncogene. 2015; 35(27):3524-34. DOI: 10.1038/onc.2015.413. View

10.

Zheng X, Carstens J, Kim J, Scheible M, Kaye J, Sugimoto H . Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015; 527(7579):525-530. PMC: 4849281. DOI: 10.1038/nature16064. View

11.

Cheng Y, Jutooru I, Chadalapaka G, Corton J, Safe S . The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration. Oncotarget. 2015; 6(13):10840-52. PMC: 4484423. DOI: 10.18632/oncotarget.3450. View

12.

Kashiwaya K, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Shinomura Y . Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis. Cancer Sci. 2009; 100(3):457-64. PMC: 11158434. DOI: 10.1111/j.1349-7006.2008.01058.x. View

13.

Han Y, Ru G, Mou X, Wang H, Ma Y, He X . AUTS2 is a potential therapeutic target for pancreatic cancer patients with liver metastases. Med Hypotheses. 2015; 85(2):203-6. DOI: 10.1016/j.mehy.2015.04.029. View

14.

Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H . MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers. PLoS One. 2015; 10(2):e0118220. PMC: 4338196. DOI: 10.1371/journal.pone.0118220. View

15.

Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai Z . Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res. 2015; 75(7):1322-31. PMC: 5884967. DOI: 10.1158/0008-5472.CAN-14-2931. View

16.

Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C . Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073):1011-1024. DOI: 10.1016/S0140-6736(16)32409-6. View

17.

Sahlgren C, Gustafsson M, Jin S, Poellinger L, Lendahl U . Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A. 2008; 105(17):6392-7. PMC: 2359811. DOI: 10.1073/pnas.0802047105. View

18.

Hashiguchi Y, Nishida N, Mimori K, Sudo T, Tanaka F, Shibata K . Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol. 2012; 40(5):1477-82. DOI: 10.3892/ijo.2012.1363. View

19.

Alzrigat M, Parraga A, Agarwal P, Zureigat H, Osterborg A, Nahi H . EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget. 2017; 8(6):10213-10224. PMC: 5354653. DOI: 10.18632/oncotarget.14378. View

20.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View